[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"catheter-complications\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:catheter-complications":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,61,87,129,158,183,210,230],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":37,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":60},"100594451","chlorhexidine-caps-for-clabsi-prevention-in-hemodialysis-a-pilot-randomized-controlled-trial-100594451",false,"NCT07019610","Chlorhexidine Caps for CLABSI Prevention in Hemodialysis: a Pilot Randomized Controlled Trial","Evaluation of Chlorhexidine Caps for Central Line Associated Blood Stream Infection Prevention in People Needing Hemodialysis: a Pilot Randomised Control Trial","ECHO-HD","Inclusion Criteria:\n\n* Age≥18\n* Able to provide informed consent\n* Kidney failure requiring a tunnelled CVC for treatment (haemodialysis)\n* 21 days BSI free\n* No known allergy to chlorhexidine and\u002For nylon and\u002For polypropylene.\n\nExclusion Criteria:\n\n* Current CLABSI\n* Known allergic to chlorhexidine and\u002For nylon and\u002For polypropylene.\n* Patients on an end-of-life pathway\n* People with a cognitive impairment and\u002For intellectual disability","ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to compare a chlorhexidine antimicrobial barrier cap in patients requiring hemodialysis treatment to the standard hemodialysis caps currently used within the Metro North Kidney Health Service.\n\nThe main questions to answer are:\n\n* Study Feasibility\n* Occurrence of infectious complications related to renal central venous catheters\n\nParticipants will be randomly allocated to receive either of the below hemodialysis caps to cover their hemodialysis catheter hub:\n\n* The standard hemodialysis cap used at the Royal Brisbane and Women's Hospital, or\n* The intervention hemodialysis cap containing chlorhexidine inside it\n\nResearchers will compare standard and chlorhexidine hemodialysis caps to see if the presence of chlorhexidine improves the occurrance of infectious complications related to the hemodialysis catheter.",[27,28,29,30,31,32,33,34,35,36],"Vascular Access Complication","Device Related Infection","Device Related Sepsis","Catheter Infection","Catheter Complications","Catheter-Related Infections","Catheter Related Complications","Hemodialysis Catheter Infection","Hemodialysis Catheter-associated Infection","Hemodialysis Complication",[38,39,40,41,42,43,44,45,46,47],"Hemodialysis Catheter","Randomised Controlled Trial","Antimicrobial Barrier Caps","Vascular access device","Hemodialysis catheter caps","Chlorhexidine cap","Central Venous Catheter","CVC","CLABSI","Central Line Associated Blood Stream Infection","NOT_YET_RECRUITING","2026-04-27",{"date":51,"type":52},"2026-04-29","ACTUAL",{"date":54,"type":21},"2026-06",{"date":56,"type":21},"2028-02",{"name":58,"class":59},"The University of Queensland","OTHER",1,{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":11,"sex":17,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":4,"studyType":22,"phases":73,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":60},"100480546","intravenous-neonatal-central-access-safety-trial-100480546","NCT05537389","Intravenous Neonatal Central Access Safety Trial","Central Lines Filtration in Newborns: a Multicenter Randomized Controlled Trial","INCAS","Inclusion Criteria:\n\n* All patients admitted to NICU with at least one central venous catheter\n\nExclusion Criteria:\n\n* Patients with peripheral venous catheter, patients with inflammatory episode at the time of enrollment","1 Hour","3 Months",{"count":72,"type":21},736,[24],"Particulate contamination due to infusion therapy (administration of parenteral nutrition and medications) carries a potential health risk for infants in neonatal intensive care units (NICU).\n\nIn-line filtration is increasingly used in critically-ill infants but its benefits, by preventing micro-particle infusion in neonates, remain to be demonstrated.\n\nIn-line filters in the intravenous administration sets prevent the infusion of particles, which may reduce infectious complications.",[76,31],"Newborn Complication","RECRUITING","2026-03-26",{"date":80,"type":52},"2026-03-30",{"date":82,"type":52},"2023-01-01",{"date":84,"type":21},"2026-06-30",{"name":86,"class":59},"University of Turin, Italy",{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":22,"phases":96,"briefSummary":97,"conditions":98,"keywords":107,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":128},"100516231","save-fistulas-the-selfwrap-assisted-arteriovenous-fistulas-study-100516231","NCT06001827","SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study","SAVE-FistulaS","Inclusion Criteria:\n\n* Age of at least 18 years\n* Referred for creation of a new AVF\n* Willing and able to comply with study requirements, communicate with the study team, and attend follow up visits over a period of 36 months\n\nExclusion Criteria:\n\n* Planned index procedure to revise or repair an existing fistula\n* Target artery inner diameter \\\u003C 2.0 mm, as measured by ultrasound while the target arm is under tourniquet pressure and anesthesia\n* Target vein inner diameter \\\u003C 2.0 mm, as measured by ultrasound while the target arm is under tourniquet pressure and anesthesia\n* Significant (at least 50%) stenosis at the target vein on the side of surgery (between the planned anastomosis site and the axillary vein), as diagnosed by preoperative ultrasound\n* Known central venous stenosis of at least 50% on the side of surgery\n* Presence of a stent or a stent graft within the access circuit\n* Known or suspected coagulation disorder that, in the opinion of the Investigator, puts too much risk on the patient for AVF creation\n* Known or suspected active infection at the time of surgery\n* Congestive heart failure NYHA class 4\n* Prior steal on the side of surgery;\n* Enrolled in another investigational drug, device, or biological study, or was previously enrolled in this study\n* Life expectancy less than 12 months\n* Expected to undergo kidney transplant surgery within 6 months of enrollment\n* Expected to undergo home hemodialysis\n* Females of childbearing potential (premenopausal and not surgically sterile) without documented current negative pregnancy test at screening\n* Presence of a comorbid condition that, in the opinion of the Investigator, may significantly confound the collection of safety and efficacy data in this study\n* Unwillingness or inability to give consent and\u002For comply with the study follow up schedule\n* Any health condition, which in the opinion of the Investigator, would interfere with the safety of the participant or the participant's ability to comply with the study.",{"count":95,"type":21},600,[24],"This is a prospective, randomized, multi-center clinical trial for chronic kidney disease (CKD) patients referred for creation of a new arteriovenous fistula (AVF) in order to assess the safety and effectiveness of SelfWrap, a bioabsorbable perivascular wrap.",[99,100,101,102,103,27,104,31,105,106],"Chronic Kidney Diseases","End Stage Renal Disease","Arteriovenous Fistula","Hemodialysis Access Failure","ESRD","Renal Failure","Catheter Dysfunction","Renal Insufficiency",[108,109,110,111,112,113,114,115,116,100,101,117],"Vascular Surgery","Vascular Access","Nephrology","Bioabsorbable","Perivascular Wrap","External Support","Hemodialysis","Dialysis","Chronic Kidney Disease","AVF","2026-02-12",{"date":120,"type":52},"2026-02-17",{"date":122,"type":52},"2024-01-03",{"date":124,"type":21},"2029-12",{"name":126,"class":127},"VenoStent","INDUSTRY",28,{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":17,"minAge":135,"maxAge":136,"enrollmentInfo":137,"targetDuration":4,"studyType":22,"phases":138,"briefSummary":139,"conditions":140,"keywords":144,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":60},"100452241","nylon-versus-polyurethane-epidural-catheters-in-patients-undergoing-major-orthopedic-surgery-100452241","NCT05168943","Nylon Versus Polyurethane Epidural Catheters In Patients Undergoing Major Orthopedic Surgery","Inclusion Criteria:\n\n* American Society of Anesthesiologists (ASA) physical status ≤ II\n* Age from 21 to 60 years\n* Body Mass Index (BMI) \\\u003C 35\n\nExclusion Criteria:\n\n* American Society of Anesthesiologists (ASA) physical status \\> II\n* Age \\\u003C 21 years or \\> 60 years\n* Body Mass Index (BMI) ≥ 35\n* Contraindications to regional anesthesia (including coagulopathy and infection at the injection site)\n* Uncooperative patients\n* Patients with known allergy to local anesthetics or opioids","21 Years","60 Years",{"count":20,"type":21},[24],"Objectives: To compare the safety and efficacy of nylon (polyamide) epidural catheter versus polyurethane epidural catheter in patients undergoing major orthopedic surgery under continuous epidural anesthesia.\n\nBackground: Continuous epidural anesthesia is the most common anesthetic technique used in orthopedic surgery. However, the use of epidural catheters is associated with complications. The insertion of the catheter may be associated with intravascular or intrathecal placement, nerve root irritation, paresthesia, kinking, hematoma, or breakage during catheter removal.\n\nPatients and Methods: This was a prospective, randomized, double-blind clinical trial; carried out on 60 patients undergoing major orthopedic surgery under continuous epidural anesthesia. Patients were randomly allocated into two equal groups; group N, using Nylon catheter, and group P, using Polyurethane catheter.",[141,31,142,105,143],"Epidural; Anesthesia","Catheter Blockage","Catheter Breakage",[145,146,147],"Epidural Anesthesia","Nylon (Polyamide) Epidural Catheter","Polyurethane Epidural Catheter","2026-01-09",{"date":150,"type":52},"2026-01-12",{"date":152,"type":52},"2025-07-01",{"date":154,"type":21},"2026-12-30",{"name":156,"class":157},"Damanhour Teaching Hospital","OTHER_GOV",{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":165,"enrollmentInfo":166,"targetDuration":4,"studyType":22,"phases":168,"briefSummary":169,"conditions":170,"keywords":171,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":60},"100455383","heparinization-vs-salinization-of-the-peripheral-venous-catheter-100455383","NCT05209841","Heparinization vs Salinization of the Peripheral Venous Catheter","Heparinization vs Salinization of the Peripheral Venous Catheter: a Randomized Clinical Trial","Inclusion Criteria:\n\n* Patients older than 18 yo, admitted to the Hospital Residencia Sant Camil\n* Patients with at least one peripheral venous line for discontinuous treatment, which has not been channeled in a medical emergency situation.\n* Written informed consent\n\nExclusion Criteria:\n\n* Allergy to heparin\n* Patients treated with unfractionated sodium heparin.\n* Patients in dialysis\n* Patients with a venous catheter indicated for diagnosis tests.\n* Patients with a venous catheter indicated for blood transfusion\n* Severe heparin-induced thrombocytopenia in recent months\n* Active uncontrollable bleeding during admission\n* Brain aneurysm or dissecting aorta, except in association with corrective surgery.\n* Confirmed \u002F suspected cerebrovascular hemorrhage\n* Severe uncontrolled hypertension\n* Severe alterations in platelet coagulation \\\u003C30,000, TP\\> 1.7 APTT ratio\\> 1.7 ratio.\n* Patient included in another clinical trial with drugs or procedures that may affect the patency of venous catheters.","100 Years",{"count":167,"type":21},3450,[24],"Randomized, double-blind clinical trial to compare the efficacy of catheter sealing with saline, compared to low-dose heparin. 3,450 patients hospitalized at the Hospital Residencia Sant Camil, in Catalonia (Spain), will be randomized to each branch of study. The primary outcome will be the percentage of catheters removed due to obstruction in each branch of study. As secondary outcomes, the number of catheter-associated phlebitis, catheter-associated bacetrihemia, extravasation, and catheter loss will be measured. For the primary outcome, a superiority analysis will be carried out in terms of the percentage of obstructed catheters in each branch of the study.",[31],[172,173],"Catheterization, Peripheral","Catheter Obstruction","2025-06-23",{"date":176,"type":52},"2025-06-25",{"date":178,"type":52},"2022-04-05",{"date":180,"type":21},"2026-07-30",{"name":182,"class":59},"Consorci Sanitari de l'Alt Penedès i Garraf",{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":190,"targetDuration":4,"studyType":22,"phases":192,"briefSummary":193,"conditions":194,"keywords":197,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":4},"100551910","complications-associated-with-multiple-central-venous-accesses-in-the-internal-jugular-vein-100551910","NCT06466226","Complications Associated With Multiple Central Venous Accesses in the Internal Jugular Vein","Incidence of Complications Associated With Multiple Central Venous Accesses in the Internal Jugular Vein: a Randomized Multicenter Non-inferiority Clinical Trial","Inclusion Criteria:\n\n* Patients with preanesthetic planning for insertion of at least two central venous catheters.\n* Adult ASA I to IV patients (over 18 years old), scheduled to undergo cardiac surgeries, vascular surgeries, major abdominal or thoracic surgeries, liver transplants and lung transplants.\n\nExclusion Criteria:\n\n* Patients with a previous history of central venous thrombosis or central venous stenosis will be excluded from the research protocol.\n* Patients without preanesthetic planning insertion of at least two central venous catheters.",{"count":191,"type":21},156,[24],"Patients at risk of significant intraoperative blood loss and\u002For potential hemodynamic instability often necessitate the placement of two or more central venous catheters, including large bore catheters. In tertiary hospitals, anesthesiologists frequently encounter patients undergoing major surgeries such as liver transplantation, lung transplantation, cardiac surgery, and vascular surgery, who require multiple central venous punctures as part of routine anesthetic management. However, most review and consensus articles do not directly address the utilization of multiple catheters in the same venous site, nor establish formal recommendations regarding this practice. The latest consensus on central venous access from the American Association of Anesthesiologists (ASA), published in 2012, briefly touches upon some aspects related to this practice but does not outline any contraindications. Thus, the investigators have identified a gap in evidence and robust prospective studies addressing the use of more than one catheter in the same site for central venous access. This lacuna underscores the importance of conducting a controlled clinical study in our institutions to establish the efficacy and safety of this approach in the perioperative context. The present study aims to evaluate the incidence of mechanical complications (such as dysrhythmias, arterial puncture, hematoma, pneumothorax\u002Fhemothorax, insertion failure, or inadequate positioning) within the first 24 hours after double puncture of the internal jugular vein compared to puncture of two distinct central vessels, in patients undergoing multiple central venous accesses during major surgeries. This study will be designed as a prospective, randomized, non-inferiority, open, parallel clinical trial with two groups for patient allocation. Patients identified for multiple central venous accesses as part of preoperative anesthetic planning will be randomly allocated to either receive two central venous accesses in two separate sites (Group I or control group) or two concurrent central venous accesses in a single internal jugular vein (Group II or intervention group). Only adult patients classified as ASA I to IV (over 18 years old), scheduled for major surgery, will be eligible for inclusion.",[195,31,196],"Central Venous Catheters","Catheter Related Complication",[198,199,200],"central venous access","complications","major surgery","2024-06-17",{"date":203,"type":52},"2024-06-20",{"date":205,"type":21},"2024-07-01",{"date":207,"type":21},"2027-12-31",{"name":209,"class":59},"Hospital Nossa Senhora da Conceicao",{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":216,"targetDuration":218,"studyType":219,"phases":4,"briefSummary":220,"conditions":221,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":226,"leadSponsor":228,"locationsCount":60},"100551012","a-study-of-stimulant-medications-infusion-through-midline-catheters-based-on-real-world-data-100551012","NCT06454552","A Study of Stimulant Medications Infusion Through Midline Catheters Based on Real-world Data","Inclusion Criteria:\n\n* Age greater than or equal to 18 years old.\n* In patients with conventional indwelling single-chamber three-way valve MC, the catheter tip is located in the axillary vein or subclavian vein of the chest wall segment.\n\nExclusion Criteria:\n\n* Those who have been placed with a central venous catheter during MC insertion.\n* Vulnerable groups, including people with mental illness, cognitive impairment, critically ill patients, minors, pregnant women, illiterates, etc.",{"count":217,"type":21},2500,"6 Months","OBSERVATIONAL","Based on the previous research, this study intends to explore the outcome of trans-MC infusion of stimulant drugs when the MC tip is located in the subclavian vein\u002Fchest wall segment axillary vein, especially to analyze the relationship between drug dose, infusion days and catheter-related complications, so as to provide a basis for the clinical application of MC infusion stimulant drugs, provide evidence for the revision of infusion practice guidelines, and ensure the safety of patients' infusion. Reduce the occurrence of adverse events, provide a basis for further expanding the clinical application scope of MC, reduce unnecessary peripherally inserted central venous catheters (PICC) and central venous catheters (CVC) and other central venous catheters, and reduce medical costs.",[31],"2024-06-11",{"date":224,"type":52},"2024-06-12",{"date":222,"type":21},{"date":227,"type":21},"2025-02-14",{"name":229,"class":59},"Sir Run Run Shaw Hospital",{"id":231,"slug":232,"hasResults":11,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":236,"eligibilityCriteria":237,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":238,"targetDuration":4,"studyType":22,"phases":240,"briefSummary":242,"conditions":243,"keywords":246,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":60},"100527574","phase-3-evaluate-the-efficacy-and-safety-of-edoxaban-on-prevention-of-catheter-related-thrombosis-crt-in-cancer-patients-100527574","NCT06149533","Evaluate the Efficacy and Safety of Edoxaban on Prevention of Catheter-related Thrombosis (CRT) in Cancer Patients","A Randomized, Multicenter, Open-Label, Control, Clinical Trial to Evaluate the Efficacy and Safety of Edoxaban on Prevention of Catheter-related Thrombosis (CRT) in Cancer Patients","Thrombosis","Inclusion Criteria:\n\n1. Age≥18.\n2. Cancer patients with a catheter-related thrombus risk prediction model score ≥ 19.6.\n3. ECOG score≤2.\n4. Expected survival period over 6 months.\n5. Malignant tumor was diagnosed by pathology and central venous catheterization was successfully completed.\n6. Signing of informed consent voluntarily.\n\nExclusion Criteria:\n\n1. Unknown location of the primary tumor.\n2. Allergy to the active ingredient of edoxaban tablets or other excipients.\n3. There is clinically significant active bleeding.\n4. Platelet \\\u003C50×109\u002FL.\n5. Liver disease with coagulopathy or clinically relevant bleeding risk.\n6. A lesion or condition with a significant risk of major bleeding, such as current or recent gastrointestinal ulcer, recent brain or spinal injury, recent brain, spinal, or ophthalmic surgery, recent intracranial hemorrhage, esophageal varices, arteriovenous malformations, vascular aneurysms, or major intravertebral or intracerebral vascular malformations.\n7. Concomitant therapy with any other anticoagulant, such as Unfractionated heparin (UFH), Low molecular heparin (Low molecular weight heparin, LMWH) (enoxaparin, dalteparin, etc.), heparin derivative (fondaparinux, etc.), oral anticoagulant (warfarin, dabigatran, rivaroxaban, apixaban, etc.), except in the special case of administration of UFH to maintain central venous catheter patency.\n8. Surgical treatment is planned for the duration of the study.\n9. Uncontrolled co-morbidities include, but are not limited to:\n\n   Serious, uncontrolled infection. Symptomatic heart failure (New York Heart Association class II-IV) or symptomatic or poorly controlled arrhythmias Uncontrolled hypertension (systolic blood pressure ≥160mmHg or diastolic blood pressure ≥100mmHg) despite standard treatment.\n\n   Any arterial thromboembolic event within 6 months before enrollment. Tumor invasion of large vessels. History of deep vein thrombosis, pulmonary embolism, or other major thromboembolism within 3 months before enrollment.\n10. History of gastrointestinal perforation within 6 months before enrollment.\n11. Pregnant or breastfeeding women.\n12. Oral contraceptives.\n13. Conditions considered unsuitable for inclusion in this study.",{"count":239,"type":21},366,[241],"PHASE3","To evaluate the efficacy and safety of edoxaban in the prevention of tumor catheter-related thrombosis (CVC\u002FPICC) in high-risk patients",[244,245,31],"Thrombosis, Venous","Cancer",[247,248,245,249],"Prevention","Catheter-related Thrombosis","Edoxaban","2023-11-20",{"date":252,"type":52},"2023-11-29",{"date":254,"type":21},"2023-11-30",{"date":256,"type":21},"2026-11-30",{"name":258,"class":59},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences"]